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Abstract 
Background: Doxycycline is an antibiotic used in combination with quinine or artesunate for malaria treatment or 
alone for malaria chemoprophylaxis. Recently, one prophylactic failure has been reported, and several studies have 
highlighted in vitro doxycycline decreased susceptibility in Plasmodium falciparum isolates from different areas. The 
genetic markers that contribute to detecting and monitoring the susceptibility of P. falciparum to doxycycline, the 
pfmdt and pftetQ genes, have recently been identified. However, these markers are not sufficient to explain in vitro 
decreased susceptibility of P. falciparum to doxycycline. In this paper, the association between polymorphism of the 
small sub-unit ribosomal RNA apicoplastic gene pfssrRNA (PFC10_API0057) and in vitro susceptibilities of P. falciparum 
isolates to doxycycline were investigated.
Methods: Doxycycline IC50 determinations using the hypoxanthine uptake inhibition assay were performed on 178 
African and Thai P. falciparum isolates. The polymorphism of pfssrRNA was investigated in these samples by standard 
PCR followed by sequencing.
Results: No point mutations were found in pfssrRNA in the Thai or African isolates, regardless of the determined IC50 
values.
Conclusions: The pfssrRNA gene is not associated with in vitro decreased susceptibility of P. falciparum to doxy-
cycline. Identifying new in vitro molecular markers associated with reduced susceptibility is needed, to survey the 
emergence of doxycycline resistance.
Keywords: Malaria, Plasmodium falciparum, In vitro, Anti-malarial, Molecular marker, Doxycycline, Small ribosomal 
sub-unit RNA gene, pfssrRNA, 16S rRNA
© 2015 Gaillard et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Doxycycline is an effective anti-malarial prophylac-
tic drug when administered as a monotherapy 1  day 
before, daily during, and for 4  weeks after return from 
travel to an area where malaria is endemic. Doxycycline 
is currently a recommended chemoprophylactic regi-
men for travellers visiting areas where malaria is endemic 
and has a high prevalence of chloroquine or multidrug 
resistance [1–3]. The World Health Organization also 
recommends doxycycline in combination with quinine 
or artesunate as the second-line treatment for uncompli-
cated Plasmodium falciparum malaria [2].
Most prophylactic failures of doxycycline against P. 
falciparum were associated with the use of inadequate, 
low doses or poor compliance [4–6]. However, resistance 
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could also explain prophylactic failures with doxycycline. 
Cyclines resistance has been documented in Plasmodium 
berghei as a consequence of minocycline drug pressure in 
a P. berghei murine malaria model [7]. Recently, one pro-
phylactic failure has been reported [8].
A Bayesian mixture modelling approach identified 
three different phenotypes (low, medium, and high dox-
ycycline IC50 phenotypic groups) among P. falciparum 
African clinical isolates [9, 10]. Using 90 isolates from 
14 African countries, it was demonstrated that increases 
in copy numbers of P. falciparum metabolite drug 
transporter gene (Pfmdt, PFE0825w) and P. falciparum 
GTPase TetQ gene (PfTetQ, PFL1710c) are associated 
with reduced susceptibility to doxycycline [11], and this 
association was later confirmed in African P. falciparum 
isolates [9]. In addition, isolates with PfTetQ KYNNNN 
motif repeats <3 are associated with in vitro reduced sus-
ceptibility to doxycycline and with a significantly higher 
probability of having an IC50 above the doxycycline 
resistance threshold of 35 µM (odds ratio of 15) [11, 12]. 
The isolate obtained from the patient with prophylactic 
resistance to doxycycline harboured two copies of pfmdt 
and two PfTetQ KYNNNN motif repeats [8], consistent 
with previous in vitro data [12].
However, some recent publications have demonstrated 
that these molecular markers were certainly not only 
encountered in cases of reduced susceptibility to doxy-
cycline [13, 14] and were not associated with resistance 
in Thai isolates [14]. Therefore, it is necessary to investi-
gate other hypotheses. Based on bacterial world, proteins 
homologue to those implicated in doxycycline resistance 
in bacteria were identified in silico in P. falciparum.
Indeed, cyclines bind to proteins S4, S7, S9, and S17 of 
the 30S small ribosomal sub-unit and various ribonucleic 
acids of the 16S ribosomal RNA, preventing the bind-
ing of aminoacyl-transfer RNA to site A of the ribosome 
and thus blocking the elongation step of translation in 
bacteria [15]. Specific mutations in genes coding these 
targets can confer resistance to tetracyclines in bacteria. 
However, no point mutation was found in small sub-unit 
plastid ribosomal homologue plasmodial genes in Afri-
can isolates (pfrps7, pfrps9, and pfrps17, although S7, S9, 
and S17) [11]. It has been also shown that resistance to 
tetracycline was mediated by mutations in the 16S rRNA 
gene, particularly in Helicobacter pylori or in Propioni-
bacterium acnes [16–18]. An analogue of this gene exists 
in P. falciparum apicoplast, the small sub-unit riboso-
mal RNA gene, the pfssrRNA gene, (PFC10_API0057) 
[19–22]. First, the pfssrRNA gene shares 58 and 62  % 
identities with the 16S rRNA gene of Propionibacterium 
acnes and Helicobacter pylori, respectively. Secondly, 
this gene belongs to the apicoplast, an organelle related 
to the chloroplast of plant cells that contains its own 
genome-encoding, prokaryote-like, ribosomal RNAs, 
tRNAs and some proteins [23]. Three studies confirmed 
the specific action of cyclines on the apicoplast of P. fal-
ciparum [24–26]. A parasite exposed to 1  µM of doxy-
cycline for 20  h presented during the next cycle (72  h), 
the inhibition of apicoplastic replication visualized by 
confocal fluorescence microscopy, electron microscopy 
and an analysis of the parasite transcriptome [24]. The 
most recently published study confirms the action of 
doxycycline on the apicoplast but in two stages, with an 
immediate toxic effect and a toxic effect measurable after 
cell division [25]. A proteomic approach confirmed the 
specific deregulation of proteins involved in apicoplast 
metabolism after doxycycline treatment [27].
Thus, the aim of this study was to identify specific point 
mutations in this plasmodial ribosomal gene, accord-
ing to what is observed in other species, to determine 
whether this gene could be involved in reduced suscep-
tibility to doxycycline. For this purpose, the apicoplastic 
pfssrRNA gene from the 89 African and 89 Thai P. falci-
parum isolates, belonging to phenotypic groups differing 
in doxycycline IC50 values and already analysed for pftetQ 
and pfmdt genes, was sequenced and analysed [9, 14].
Methods
Plasmodium falciparum isolates
A total of 89 African P. falciparum isolates, obtained 
at the French National Reference Centre for Imported 
Malaria, Hôpital Bichat, Paris, from patients hospitalized 
with malaria after having returned to France between 
January 2006 and December 2010, and 89 isolates 
obtained from the Shoklo Malaria Research Unit (Mae 
Sot, Thailand) from patients infected with P. falciparum 
from 2001 to 2010, were used. These isolates were pre-
viously tested to evaluate their pfmdt and pftetQ genes 
copy numbers [9, 14].
Consent
Informed consent was not required as the sampling pro-
cedures and testing are part of the French national rec-
ommendations for the care and surveillance of malaria.
Concerning the Thai isolates, written informed consent 
translated into the patient’s own language was obtained 
from each participant, whose signature was witnessed. 
The studies were approved by the Ethics Committees of 
the Faculty of Tropical Medicine, Mahidol University and 
Oxford University.
Amplification and sequencing of pfssrRNA gene
PfssrRNA (PFC10_API0057) was amplified by polymer-
ase chain reaction (PCR) using the following primers: 
5′-AGCTAATGGTGAGATTTGAACTCA-3′ (forward) 
and 5′-CGTCGTGAGACAGTTCGGTC-3′ (reverse) 
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(Eurogentec, Angers, France), designed with the NCBI/
Primer-BLAST online tool.
The reaction mixture included 2  µl of genomic DNA, 
2.5 µl of 10× reaction buffer (Eurogentec), 0.5 µM of each 
primer, 200  µM of deoxynucleoside triphosphate mix-
ture (dGTP, dATP, dTTP and dCTP) (Euromedex, Souf-
felweyersheim, France), and 1.5  mM of MgCl2 and 1.25 
units of RedGoldStar® DNA polymerase (Eurogentec) 
in a final volume of 25 µL. The thermal cycler (T3 Biom-
etra, Archamps, France) was programmed as follows: 
an initial 94 °C for 2 min followed by 40 cycles of 94 °C 
for 30 s, 55  °C for 30 s and 60  °C for 2 min, and a final 
extension step of 60 °C for 5 min. The PCR products were 
loaded on 1 % agarose gel containing 0.5 μg/mL ethidium 
bromide. Amplicons were purified using the QIAquick 
96 PCR BioRobot Kit and an automated protocol on 
the BioRobot 8000 workstation (Qiagen, Courtaboeuf, 
France). The purified fragments were sequenced using 
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems) using the following primers: 5′-ACTAGTG 
TATTTCGGTTAACAGCCG-3′ (forward), 5′-ACCCT 
TATCAAGAGTATGTTTTAACCAT-3′ (reverse) and 
Pf_SSU_rRNA_R1481 CTTAAGAACTTATTCACCG 
CTA (reverse). The sequence reaction products were 
purified using the BigDye XTerminator® Purification 
Kit (Applied Biosystems), in accordance with the man-
ufacturer’s instructions. The purified products were 
sequenced using an ABI Prism 3100 analyser (Applied 
Biosystems), and the sequences were analysed using Vec-
tor NTI advance (TM) software (version 11, Invitrogen, 
Cergy Pontoise, France).
Results
In Helicobacter pylori, tetracycline resistance has not 
been associated with efflux or ribosomal protection pro-
teins but rather attributed to mutations in the 16S rRNA-
encoding genes that affect the binding site of tetracycline 
[16–18]. Tetracycline resistance mediated by mutations 
in the 16S rRNA was first found in Propionibacterium 
acnes, and a mutation from G to C was reported at posi-
tion 1058 (Escherichia coli numbering) in their 16S rRNA 
genes [17]. A triplet mutation in the same 16S rRNA 
domain (965–967; E. coli numbering) was also found [24, 
28–30] and is located in the primary tetracycline-binding 
site [1, 15]. However, the sequencing of pfssrRNA did not 
reveal a polymorphism in P. falciparum. There was no 
single nucleotide polymorphism in the pfssrRNA gene 
in either the 89 African isolates, regardless of the pheno-
typic group for doxycycline (group A of low doxycycline 
IC50 [mean IC50 = 3.88 µM; confident interval 95 % (CI 
95  %) [3.39–4.37], no  =  30], group B of moderate IC50 
[mean IC50 = 16.97 µM; CI 95 % [16.45–17.49]; no = 30]) 
and group C of high IC50 [mean IC50  =  34.60  µM, CI 
95 % [31.3–37.9], no = 29), or the 89 Thai isolates (group 
A [mean IC50 = 3.64 µM, CI 95 % [3.29–3.99], no = 30], 
group B [mean IC50 =  14.73 µM, CI 95 % [14.6–14.85], 
no = 30] and group C [mean IC50 = 28.94 µM, CI 95 % 
[26.51–31.37], no = 29]). No sequence polymorphism in 
the pfssrRNA gene was observed by comparison with the 
reference strain 3D7. This gene was not associated with 
reduced susceptibility to doxycycline in either African or 
Thai P. falciparum isolates and the small sub-unit riboso-
mal RNA seemed to be not a target for doxycycline.
Conclusions
The decreased susceptibility of P. falciparum to doxy-
cycline is certainly multigenic. Pfmdt and pftetQ genes 
polymorphism and number of copies are involved partly 
to the decreased susceptibility. Intensive research into 
identifying in  vitro markers associated with decreased 
susceptibility should allow survey of the emergence 
of doxycycline resistance. Another hypothesis to be 
explored is some apicoplastic genes, which could be 
involved in artemisinin resistance [31], such as arps10, 
encoding the apicoplast ribosomal protein S10 precursor, 
and fd, encoding the ferredoxin protein, a key component 
of the apicoplast electron transport chain.
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